Sequenom, Inc. Shareholder Lawsuit

PRLog (Press Release) - May 04, 2009 -
A group of angry investors filed a securities class action lawsuit United States District Court for the Southern District of California on behalf of all persons who purchased or otherwise acquired securities of Sequenom, Inc. (NASDAQ:SQNM) between June 4, 2008 and April 29, 2009 against Sequenom, Inc and certain officers and directors over alleged violations of Federal Securities Laws.

Those who purchased Sequenom, Inc. (NASDAQ:SQNM) shares between June 04, 2008 and April 28, 2009 have certain options and should contact the Shareholders Foundation. There are strict and short deadlines running. (Deadline: June 29, 2009)

Email: mail@shareholdersfoundation.com

Or

call us at: +1 (858) 779 - 1554

According to the complaint the plaintiff alleges that Sequenom, Inc and certain of its officers and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by issuing false and misleading statements between June 04, 2008 and April 28, 2009. The Complaint alleges that on April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because of employee mishandling of data and results. As a result, in after-market trading, Sequenom stock lost more than two-thirds of its trading value, falling from $14.91 to $4.69.
A further investigation will now be conducted by the law firm on the test results and data for all products, not just SEQureDxTM. Sequenom, Inc announced that multiple prior press releases and public statements concerning SEQureDxTM can no longer be relied upon, including press releases the Company issued on June 4, 2008, September 23, 2008, December 1, 2008, January 28, 2009, and February 3, 2009. The shares of Sequenom, Inc. (NASDAQ:SQNM) continued to fall on Thursday to $3.41 per share.
Sequenom, Inc. is a diagnostic testing and genetics analysis company and is focused on providing products, services, diagnostic testing, applications and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock and other areas of research.  Sequenom, Inc. is located in San Diego, California and had $41million in total revenue in 2007 and $47.15million in 2008.  

Those who purchased Sequenom, Inc. (NASDAQ:SQNM) shares between June 04, 2008 and April 28, 2009 have certain options and should contact the Shareholders Foundation. There are strict and short deadlines running. (Deadline: June 29, 2009)

Email: mail@shareholdersfoundation.com

or

call us at: +1 (858) 779 - 1554

Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423 -
92108 San Diego
Tel:+1-(858)-779-1554
Fax:+1-(858)-605-5739
mail@shareholdersfoundation.com
www.ShareholdersFoundation.com
_____________________________________________________________________________________

Photo:
http://www.prlog.org/10229462/1